Skip to main content
. 2020 Nov 23;8(4):679–685. doi: 10.1016/j.esxm.2020.09.002

Table 1.

Characteristics of the participants with and without PD

N With PD N Without PD P
Age (years), median (Q1–Q3) 63 52 (41–64) 1,119 45 (37–55) <.001
Age groups (years), n (%)
 30–39 63 13 (20.6) 1,119 379 (33.9) <.001
 40–49 14 (22.2) 294 (26.3)
 50–59 17 (27.0) 252 (22.5)
 60–69 9 (14.3) 146 (13.0)
 ≥70 10 (15.9) 48 (4.3)
Regions, n (%)
 West Anatolia 63 4 (6.3) 1,119 114 (10.2) .005
 Northeast Anatolia 6 (9.5) 24 (2.1)
 East Black Sea 2 (3.2) 39 (3.5)
 West Black Sea 3 (4.8) 64 (5.7)
 Central East Anatolia 4 (6.3) 44 (3.9)
 Central Anatolia 0 (0.0) 49 (4.4)
 Southeast Anatolia 7 (11.1) 83 (7.4)
 Mediterranean 12 (19.0) 141 (12.6)
 Aegean 5 (7.9) 163 (14.6)
 Istanbul 7 (11.1) 226 (20.2)
 East Marmara 10 (15.9) 110 (9.8)
 West Marmara 3 (4.8) 62 (5.5)
BMI, median (Q1–Q3) 63 26.99 (23.15–29.41) 1,077 25.95 (24.06–28.4) .260
Obesity, n (%) 63 14 (22.2) 1,077 166 (15.4) .150
Smoking status, n (%) 63 1,105
 Smoker 46 (73.0) 673 (60.9) .036
 Ex-smoker 12 (19.0) 197 (17.8)
 Never smoked 5 (7.9) 235 (21.3)
Comorbidity, n (%)
 Diabetes mellitus 63 11 (17.5) 1,119 103 (9.2) .045
 Hypertension 63 9 (14.3) 1,119 77 (6.9) .041
 Heart failure 63 5 (7.9) 1,119 28 (2.5) .027
 Atherosclerosis 63 5 (7.9) 1,119 54 (4.8) .237
 Hyperlipidemia 63 1 (1.6) 1,119 10 (0.9) .454
 Hyperuricemia (gout) 63 0 (0.0) 1,119 1 (0.1) -
 Rheumatoid arthritis 63 0 (0.0) 1,119 4 (0.4) -
 Psoriasis 63 0 (0.0) 1,119 6 (0.5) 1.000
 Urethritis 63 0 (0.0) 1,119 2 (0.2) -
 Kidney/urinary stone disease 63 2 (3.2) 1,119 23 (2.1) .389
 Benign prostate hyperplasia 63 0 (0.0) 1,119 13 (1.2) 1.000
Previous operation, n (%) 62 29 (46.8) 1,095 397 (36.3) .095
Urinary catheterization for any reason, n (%) 62 11 (17.7) 1,085 113 (10.4) .071

BMI, body mass index; PD = Peyronie's disease.

Mann-Whitney U test.

Chi-square test.

Fisher's exact test.